Wang Yan, Wang Wenling, Dong Hongming, Wang Gang, Chen Wanghua, Chen Juan, Chen Weiwei
Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Department of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Front Oncol. 2023 Mar 1;13:1017237. doi: 10.3389/fonc.2023.1017237. eCollection 2023.
Fluoropyrimidine is an important component of systemic chemotherapy for colorectal cancer (CRC). Fluoropyrimidine-induced cardiotoxicity (FIC) may result in delay and discontinuation of chemotherapy and, in severe cases, can even be life-threatening. To date, risk factors for FIC have not been well identified. This cohort study aimed to identify the predictors of FIC in CRC patients and develop a risk prediction nomogram model.
Between January 1, 2018 and December 31, 2020, colorectal cancer patients who received 5-fluoropyrimidine(5-Fu)/capecitabine-based chemotherapy in Affiliated Cancer Hospital of Guizhou Medical University were included. FIC was defined as an adverse cardiovascular event related to fluoropyrimidine that occurred during or within four weeks of completing chemotherapy. Risk factors were determined by LASSO algorithm and multivariate logistic regression analysis. Nomogram for predicting 5-Fu-induced cardiotoxicity was established and internally validated. The concordance index (C-index) and calibration curve were used to evaluate the nomogram's discrimination and accuracy.
A total of 916 patients were included for analysis, and 200 [21.8%,95% confidence interval (CI):19.12%-24.47%] experienced FIC. LASSO algorithm and multivariate logistic regression analysis determined that chemotherapy ≤3 cycles (OR=4.694, 95%CI=3.184-6.92), age≥ 60 (OR=1.678, 95%CI=1.143-2.464), BMI>22.97 (OR=1.77, 95%CI=1.202-2.606), and simultaneous use of bevacizumab (OR=2.922, 95%CI=1.835-4.653) were significant risk factors, and were included in the prediction model for 5-Fu induced cardiotoxicity. The C-index (95%CI) was 0.751 (0.706-0.795) by internal validation. For patients treated with capecitabine-based regimen, the incidence of FIC increased with the absolute value of neutrophils (OR=5.177, 95%CI=1.684-15.549) and eosinophils (OR=3.377,95% CI=1.237-9.22).
Our study identified risk factors for FIC and established a prediction nomogram model based on chemotherapy cycle, age, BMI and use of target therapy for 5-FU induced Cardiotoxicity. The discriminative prediction model can be used for patient counselling and risk-stratification before undergoing chemotherapy in colorectal cancer.
氟尿嘧啶是结直肠癌(CRC)全身化疗的重要组成部分。氟尿嘧啶诱导的心脏毒性(FIC)可能导致化疗延迟和中断,严重时甚至会危及生命。迄今为止,FIC的危险因素尚未得到很好的识别。这项队列研究旨在确定CRC患者中FIC的预测因素,并建立一个风险预测列线图模型。
纳入2018年1月1日至2020年12月31日期间在贵州医科大学附属肿瘤医院接受以5-氟尿嘧啶(5-Fu)/卡培他滨为基础化疗的结直肠癌患者。FIC被定义为在化疗期间或完成化疗后四周内发生的与氟尿嘧啶相关的不良心血管事件。通过LASSO算法和多因素逻辑回归分析确定危险因素。建立预测5-Fu诱导心脏毒性的列线图并进行内部验证。使用一致性指数(C指数)和校准曲线评估列线图的辨别力和准确性。
共纳入916例患者进行分析,200例(21.8%,95%置信区间[CI]:19.12%-24.47%)发生FIC。LASSO算法和多因素逻辑回归分析确定化疗≤3周期(OR=4.694,95%CI=3.184-6.92)、年龄≥60岁(OR=1.678,95%CI=1.143-2.464)、BMI>22.97(OR=1.77,95%CI=1.202-2.606)以及同时使用贝伐单抗(OR=2.922,95%CI=1.835-4.653)是显著危险因素,并被纳入5-Fu诱导心脏毒性的预测模型。通过内部验证,C指数(95%CI)为0.751(0.706-0.795)。对于接受以卡培他滨为基础方案治疗的患者,FIC的发生率随中性粒细胞(OR=5.177,95%CI=1.684-15.549)和嗜酸性粒细胞(OR=3.377,95%CI=1.237-9.22)绝对值的增加而升高。
我们的研究确定了FIC的危险因素,并建立了一个基于化疗周期、年龄、BMI和靶向治疗使用情况的5-FU诱导心脏毒性预测列线图模型。该判别性预测模型可用于结直肠癌患者化疗前的咨询和风险分层。